Table 1.
Baseline characteristics of the total study population before propensity score matching (1:1)
| NHRs with currenta use of therapeutic dose anticoagulant (P1, before 1:1 propensity score matching) (n = 792) | NHRs with no current use of therapeutic dose anticoagulant (P2, before 1:1 propensity score matching) (n = 2,729) | P-value | SMD | |
|---|---|---|---|---|
| Demographical data | ||||
| Age (mean in years), med (IQR) | 86 [82, 91] | 83 [78, 90] | <0.001 | 0.298 |
| Sex, n (%) Male Female |
326 (41.2) 466 (58.8) |
978 (35.9) 1751 (64.2) |
0.008 | 0.108 |
| Clinical data Co-morbidities (n, %) |
||||
| Congestive heart failure | 13 (1.6) | 8 (0.3) | <0.001 | 0.138 |
| Hypertension | 0 (0.0) | 1 (0.0) | 1.000 | 0.027 |
| Obesity | 26 (3.6) | 43 (1.8) | 0.005 | 0.112 |
| Dementia | 417 (53.0) | 1563 (58.1) | 0.013 | 0.102 |
| Cardiovascular disease | 646 (82.1) | 954 (35.4) | <0.001 | 1.075 |
| Cerebrovascular disease | 402 (51.1) | 901 (33.5) | <0.001 | 0.361 |
| Diabetes mellitus | 206 (26.2) | 626 (23.3) | 0.099 | 0.068 |
| Pulmonary disease | 171 (21.7) | 443 (16.5) | 0.001 | 0.134 |
| Renal insufficiency | 180 (22.9) | 423 (15.7) | <0.001 | 0.184 |
| Parkinson’s disease | 45 (5.7) | 179 (6.6) | 0.389 | 0.039 |
| Type of ward (n, %) | <0.001 | 0.302 | ||
| Psychogeriatrics | 311 (39.3) | 1337 (49.0) | ||
| Somatics | 219 (27.7) | 447 (16.4) | ||
| Short-term stayb | 134 (16.9) | 406 (14.9) | ||
| Other ward, not specified | 128 (16.1) | 539 (19.8) | ||
| Time in pandemic, days (mean) | 44.69 (13.72) | 44.31 (13.75) | 0.492 | 0.028 |
| Days to event (mean, SD) | 25.73 (15.87) | 24.32 (16.02) | 0.029 | 0.302 |
| Outcome (n, %) | ||||
| All- cause mortalityc | 179 (22.6) | 708 (26.0) | 0.061 | 0.079 |
NHRs, nursing home residents.
aCurrent use was defined as the use in the last 30 days before start of COVID-19.
bPrimary care and geriatric rehabilitation.
cMortality within 30 days after COVID-19 diagnosis.